Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P.
Berg SA, et al.
Urol Oncol. 2024 Nov 4:S1078-1439(24)00701-4. doi: 10.1016/j.urolonc.2024.10.022. Online ahead of print.
Urol Oncol. 2024.
PMID: 39500687
Free article.
Review.